Viatris launches tender offer for Pacira BioSciences at $36.50 per share.
Viatris Inc. announced that its wholly owned subsidiary has commenced a cash tender offer to acquire all outstanding shares of Pacira BioSciences at $36.50 per share.
Capital flows, CMO moves, M&A. Eight editions a day, seven tiers, from the chopped neck.
Fresh today 7 new items in the 00:00 utc editionJump to the new edition ↓Viatris Inc. announced that its wholly owned subsidiary has commenced a cash tender offer to acquire all outstanding shares of Pacira BioSciences at $36.50 per share.
Pantheon has closed its latest global private equity secondaries program with $6 billion in commitments, significantly exceeding the strategy's original $3.5 billion target.
The RealReal reported Q3 2026 earnings that topped expectations, with CEO Rati Levesque noting a fundamental change in how consumers shop for luxury fashion.
Real estate giant CBRE announced a $1 billion acquisition to expand its data center operations, reflecting real estate's growing reliance on the tech cycle.
Nasdaq Private Market completed its acquisition of Nasdaq Fund Secondaries and named Marshall Widom head of the newly integrated fund secondaries business.
Five companies are launching initial public offerings this week across India, including EAAA India Alternatives, BLS Polymers, MK Sons Fine Jewels, and SFC Environmental Tech, with a combined capital target of ₹2,600 crore.
Kering, the owner of Gucci, Bottega Veneta and other high-end labels, reported a 1% decrease in revenue as the luxury market continues to see sharp drops in consumer demand.
The branded-identity layer Chiefs of Staff and heritage CMOs route through: your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.